Navigation Links
AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project
Date:2/6/2008

Donation Supports Three-Year Program to Increase Healthy Lifestyles at N.C.

Department of Transportation

RALEIGH, N.C., Feb. 6 /PRNewswire/ -- AstraZeneca L.P. today expanded its commitment to building healthy lifestyles in North Carolina by making a $1.5 million charitable donation to N.C. Prevention Partners. The donation, secured by the North Carolina State Health Plan, will fund for three years a comprehensive worksite wellness program available to employees at the N.C. Department of Transportation (N.C. DOT).

"We are delighted to make this contribution to N.C. Prevention Partners to fund a program that will empower N.C. DOT employees to embrace healthier living," said Michael Draine, National Sales Director for Managed Markets at AstraZeneca. "This program is exemplary of AstraZeneca's commitment to helping communities across the nation -- and worldwide -- promote health and healthy behaviors."

The new program, called the N.C. Department of Transportation Wellness Initiative, will allow the State Health Plan and its partners to measure the effect of a comprehensive worksite wellness program on lifestyle and health behaviors of its members and on employment-related outcomes. N.C. Prevention Partners, a statewide non-profit organization, will administer the funds and provide program oversight.

Seventy percent of the State Health Plan's medical and pharmacy claims costs are attributed to mostly preventable diseases related to poor nutrition, obesity, lack of exercise, tobacco use and unmanaged stress. The new Wellness Initiative is intended to counter these behaviors through education and interventions with participating DOT employees.

"We are pleased to be a part of this project that I believe will make a positive and meaningful impact on employees' health outcomes," said George C. Stokes, executive administrator of the State Health Plan. "We look forward to helping the N.C. DOT build a culture of wellness and foster a healthier, more productive workforce."

For nearly a decade, AstraZeneca has supported services in North Carolina intended to improve health and patient care. Beginning with the Carolina Community Care program in 1998, AstraZeneca has helped North Carolina residents with prescription savings programs, health management tools and other initiatives to support better health outcomes. In addition to its work in North Carolina, AstraZeneca supports health and wellness initiatives nationwide.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com

Media Contact:

Christa Peisinger

AstraZeneca

302-886-1013


'/>"/>
SOURCE AstraZeneca Pharmaceuticals L.P.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... , ... Are You Concerned About Mold In Your Home or Workplace? ... Companies in VA, MD and DC, recently completed its application for the new District ... in the district of Columbia is a good thing stated John Taylor, Owner of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... Los Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... a lien basis to help personal injury victims find high quality medical care. When ... the Los Angeles area. Fast forward to present day and the now ten-page directory ...
(Date:12/2/2016)... ... December 02, 2016 , ... FlexiSpot, ... of its 60-day free trial program for all of the company’s desktop riser ... a truly hassle free experience. , FlexiSpot’s unique desktop risers use an advanced ...
(Date:12/2/2016)... New York, NY (PRWEB) , ... December 02, 2016 , ... ... Through an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to ... “Early on I learned that medicine is about more than making diagnoses and prescribing ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- Seno Medical Instruments, Inc., the company pioneering the development ... the process of diagnosing breast cancer, today announced that ... surveillance and clinical follow-up study at the 2016 ... from December 6-10, 2016 at the Henry B. Gonzalez ... . Seno Medical Instruments will present two ...
(Date:12/5/2016)... and TAIPEI, Taiwan , Dec. ... months of treatment ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) ... a significantly better safety and tolerability profile of ropeginterferon alfa-2b ... from PROUD-PV and the ongoing long-term follow-up trial CONTINUATION-PV to ... PharmaEssentia intends to present this data to the FDA ...
(Date:12/4/2016)... 3, 2016 Sickle cell disease (SCD) is ... blood cells that get stuck in veins and block ... failure, and complications leading to death. Each year, approximately ... and most of them lack access to comprehensive care ... long-term therapy for SCD, a pill called hydroxyurea approved ...
Breaking Medicine Technology: